慢性鼻窦炎生产力损失由什么驱动?SNOT-22子域分析
这项前瞻性多机构观察性队列研究纳入198例难治性慢性鼻窦炎患者,评估SNOT-22五个子域与生产力损失的关系。结果显示心理功能障碍(Rs=0.428)和睡眠功能障碍(Rs=0.355)子域与生产力损失相关,SNOT-22总分亦与货币化生产力损失相关(Rs=0.366)。
要点
- SNOT-22心理功能障碍子域与生产力损失相关(Rs=0.428,P<.001)。
- SNOT-22睡眠功能障碍子域与生产力损失相关(Rs=0.355,P<.001)。
- 合并免疫缺陷、吸烟和激素依赖者年均生产力成本高于平均水平。
核心结论
- SNOT-22睡眠和心理子域损伤与生产力损失相关。
- 合并免疫缺陷、吸烟和激素依赖的患者生产力损失高于平均水平。
- 在标准症状控制基础上针对性管理心理和睡眠功能障碍可能改善以患者为中心的护理并减少CRS年度经济负担。
研究设计与样本
- 前瞻性、多机构、观察性队列研究,纳入198例难治性慢性鼻窦炎患者,入组时间2012年8月至2015年6月。
- 基线生活质量采用SNOT-22五个子域评估。
- 生产力损失时间由患者报告的年度缺勤、Presenteeism和休闲时间损失确定,并使用2012年美国国家人口普查和2013年劳工统计局的年度日工资率货币化。
主要发现
- 生产力损失与SNOT-22心理功能障碍子域评分相关(Spearman相关系数Rs=0.428,P<.001)。
- 生产力损失与SNOT-22睡眠功能障碍子域评分相关(Rs=0.355,P<.001)。
- 更高的SNOT-22总分也与货币化生产力损失增加显著相关(Rs=0.366,P<.001)。
- 患者年均生产力成本为11,820美元/人,而合并免疫缺陷(23,285美元/人)、吸烟(23,195美元/人)和激素依赖(18,910美元/人)的患者报告的年均生产力成本高于平均水平。
- 多变量线性回归发现调整后心理子域(13,300美元/人,P<.001)和睡眠功能障碍子域(9,275美元/人,P<.001)的年生产力成本最大。
关键数值与推荐
- SNOT-22心理功能障碍子域与生产力损失的Spearman相关系数Rs=0.428(P<.001)。
- SNOT-22睡眠功能障碍子域与生产力损失的Spearman相关系数Rs=0.355(P<.001)。
- SNOT-22总分与货币化生产力损失的Spearman相关系数Rs=0.366(P<.001)。
- 平均年生产力成本为11,820美元/患者;合并免疫缺陷者为23,285美元/患者,吸烟者为23,195美元/患者,激素依赖者为18,910美元/患者。
- 多变量线性回归中,调整后心理子域年生产力成本为13,300美元/患者(P<.001),睡眠功能障碍子域为9,275美元/患者(P<.001)。
临床怎么用
- 在标准症状控制基础上,针对性管理心理和睡眠功能障碍可能改善以患者为中心的护理并减少CRS年度经济负担。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Previous studies have shown declines in productivity due to chronic rhinosinusitis (CRS) are correlated with disease-specific quality-of-life (QOL) measures. However, it is unclear which symptom domains contribute primarily to productivity loss. This investigation sought to assess the association between CRS-specific QOL subdomain impairment and productivity loss. STUDY DESIGN: Prospective, multi-institutional, observational cohort study. METHODS: There were 198 patients with refractory CRS enrolled between August 2012 and June 2015. Baseline QOL measures were obtained across five subdomains of the 22-item SinoNasal Outcome Test (SNOT-22). Lost productivity time was determined from patient-reported measures of annual absenteeism, presenteeism, and lost leisure time, and then monetized using annual daily wage rates from the 2012 US National Census and 2013 Department of Labor statistics. RESULTS: Productivity losses correlated with impairments in both SNOT-22 psychological dysfunction (Spearman correlation coefficient [Rs] = 0.428, P < .001), and sleep dysfunction domain scores (Rs = 0.355, P < .001). Higher SNOT-22 total scores also significantly correlated with increased monetized productivity losses (Rs = 0.366, P < .001). The mean annual productivity cost was $11,820/patient, whereas patients with comorbid immunodeficiency ($23,285/patient), tobacco use ($23,195/patient), and steroid dependency ($18,910/patient) reported higher than average annual productivity costs. Multivariate linear regression found maximum annual productivity costs in adjusted psychological ($13,300/patient, P < .001) and sleep dysfunction ($9,275/patient, P < .001) domains. CONCLUSIONS: Impairments in sleep and psychological SNOT-22 domains correlate with productivity losses. Patients with comorbid immunodeficiency, smoking, and steroid dependency had higher than average productivity losses. Targeted management of psychological and sleep dysfunction in combination with standard symptom control may improve patient-centered care and reduce the annual economic burden of CRS. LEVEL OF EVIDENCE: 2c. Laryngoscope, 128:23-30, 2018.
引用
- Chowdhury NI, Mace JC, Smith TL, et al. What drives productivity loss in chronic rhinosinusitis? A SNOT-22 subdomain analysis. Laryngoscope. 2017. PMID: 28600803. doi:10.1002/lary.26723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。